Company profile: OrsoBio
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapies for severe metabolic disorders, including TLC-3595 (selective ACC2 inhibitor) to improve insulin sensitivity in type 2 diabetes; TLC-2716 (liver-targeted LXR inverse agonist) to lower plasma triglycerides and cholesterol in severe dyslipidemias; mitochondrial protonophores (TLC-6740, TLC-1235) to increase energy expenditure; and an ACMSD inhibitor to augment NAD+ and mitochondrial function in liver/kidney dysfunction.
Products and services
- Mitochondrial Protonophores (TLC-6740, TLC-1235): Mitochondria-directed compounds that increase energy expenditure and aim to improve metabolic and cardiovascular health in patients with metabolic disorders
- TLC-2716 (LXR inverse agonist): Liver-targeted inhibitor of the Liver X Receptor designed to reduce plasma triglycerides and cholesterol in patients with severe dyslipidemias
- TLC-3595 (ACC2 inhibitor): Selective inhibitor of acetyl-CoA carboxylase 2 (ACC2) aimed at improving insulin sensitivity in patients with type 2 diabetes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OrsoBio
Zystor
HQ: United States
Website
- Description: Provider of enzyme replacement therapies under development for the treatment of lysosomal storage diseases; privately held biotechnology company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zystor company profile →
Ocera Therapeutics
HQ: United States
Website
- Description: Provider of novel therapeutics in development for patients with acute and chronic liver disease, as a clinical-stage biopharmaceutical company focused on development and commercialization in an area of high unmet medical need; HE clinical development includes a recently completed Phase 2b trial, STOP-HE, which evaluated safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ocera Therapeutics company profile →
HepaRegeniX
HQ: Germany
Website
- Description: Provider of drug candidates targeting MKK4 to restore hepatocyte regeneration for acute and chronic liver diseases. Pipeline includes HRX-0215, a first-in-class MKK4 inhibitor in clinical trials, and HRX-0233, a second MKK4 inhibitor under preclinical collaborations for cancer combination therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HepaRegeniX company profile →
Rediscovery Life Sciences
HQ: United States
Website
- Description: Provider of biopharma drug development, creating medicines with less risk through drug repurposing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rediscovery Life Sciences company profile →
MRM Health
HQ: Belgium
Website
- Description: Provider of microbiome-based therapeutics and development platforms, including the CORAL platform to design optimized microbial consortia, SHIME simulator of the human gut, and Optimized Consortia therapeutics. Offers clinical programs in inflammatory bowel diseases (Ulcerative Colitis, Pouchitis) with MH002, and preclinical programs in CNS, metabolic (Type 2 Diabetes, NAFLD/NASH) and auto-immune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MRM Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OrsoBio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OrsoBio
2.2 - Growth funds investing in similar companies to OrsoBio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OrsoBio
4.2 - Public trading comparable groups for OrsoBio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →